Preview

Кардиология

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Доступ платный или только для Подписчиков

Гиполипидемическая терапия при хронической болезни почек: влияние на риск развития сердечно-сосудистых заболеваний и дисфункцию почек

https://doi.org/10.18087/cardio.2019.2.10231

Полный текст:

Аннотация

Неуклонный рост распространенности хронической болезни почек (ХБП) представляет собой серьезную проблему общественного здравоохранения, поскольку ХБП потенциально приводит к развитию терминальной стадии почечной недостаточности (ПН), требующей высокозатратной заместительной терапии, и тесно связана с повышенным риском развития сердечно-сосудистых заболеваний (ССЗ), из-за которых умирает большинство пациентов. На прогрессирование дисфункции почек и развитие ССЗ значительное влияние оказывают гипер- и дислипидемии. В настоящем обзоре представлены результаты исследований по оценке влияния гиполипидемической терапии на снижение риска развития ССЗ и замедление дисфункции почек у больных ХБП на преддиализной и диализной стадиях ПН, а также у пациентов с почечным трансплантатом. Кроме того, представлены рекомендации по питанию и новые терапевтические подходы к использованию липидснижающей терапии у больных ХБП, а также перспективы применения новых гиполипидемических препаратов.

Об авторах

К. А. Айтбаев
НИИ молекулярной биологии и медицины при Национальном центре кардиологии и терапии им. акад. М. Миррахимова.
Кыргызстан
Бишкек.


И. Т. Муркамилов
Кыргызская государственная медицинская академия им. И. К. Ахунбаева; Кыргызско-Российский Славянский университет им. первого Президента России Б. Н. Ельцина.
Кыргызстан
Бишкек.


В. В. Фомин
ФГАОУ ВО Первый Московский государственный медицинский университет им. И. М. Сеченова Минздрава России (Сеченовский Университет),
Россия
Москва.


Список литературы

1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1–266.

2. Zoccali C., Kramer A., Jager K.J. Epidemiology of CKD in Europe: an uncertain scenario. Nephrol Dial Transplant 2010; 25: 1731– 1733. DOI: https://doi.org/10.1093/ndt/gfq250.

3. Smirnov A.V., Shilov E.M., Dobronravov V.A. et al. Nacional’nye rekomendacii. Hronicheskaja bolezn’ pochek: osnovnye principy skrininga, diagnostiki, profilaktiki i podhody k lecheniju. Clinical Nephrology 2012;4:27–34. Russian (Смирнов А.В., Шилов Е.М., Добронравов В.А. и др. Национальные рекомендации. Хрони-ческая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Клиническая нефрология 2012;4:27–34).

4. Liyanage T., Ninomiya T., Jha V. et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 2015;385:1975–1982. DOI: http://dx.doi.org/10.1016/S0140-6736(14)61601-9.

5. Moiseev V.S., Muhin N.A., Smirnov A.V. et al. National recommendations. Cardiovascular risk and chronic kidney disease: cardionephroprotective strategies 2013. Klinicheskaja Farmakologija i Terapija 2014;23(4):4–27. Russian (Моисеев В.С., Мухин Н.А., Смирнов А.В. и др. Национальные рекомендации «Сердечно-сосудистый риск и хроническая болезнь почек: стратегия кардио-нефропротекции. Клиническая фармакология и терапия 2014;23(3):4–27).

6. Shishkova V.N. Chronic kidney disease and cardiovascular diseases: focus on atrial fibrillation. Ration Pharmacother Cardiol 2015;11(2):196–201. Russian (Шишкова В.Н. Хроническая болезнь почек и сердечно-сосудистая заболеваемость: фокус на фибрилляцию предсердий. Рациональная фармакотерапия в кардиологии 2015;11(2):196–201).

7. de Jager D.J., Grootendorst D.C., Jager K.J. et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 2009;302(16):1782–1789. DOI: 10.1001/jama.2009.1488.

8. Tonelli M., Muntner P., Lloyd A. et al. Association between LDL-C and risk of myocardial infarction in CKD. J Am Soc Nephrol 2013;24:979–986. DOI: 10.1681/ASN.2012080870.

9. Wilson P.W., D’Agostino R.B., Levy D. et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837–1847. PMID:9603539.

10. Stamler J., Wentworth D., Neaton J.D. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256:2823–2828. DOI: 10.1001/jama.1986.03380200061022.

11. Degoulet P., Legrain M., Reach I. et al. Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. Nephron 1982;31:103–110. DOI: https://doi.org/10.1159/000182627.

12. Nazarov A.V., Zhdanova T.V., Urazlina S.E., Istomina A.S. Dyslipidemia in patients with chronic kidney disease. Ural’skiy meditsinskiy zhurnal 2011;2:124–127. Russian (Назаров А.В., Жданова Т.В., Уразлина С.Е., Истомина А.С. Нарушения липид-ного обмена у пациентов с хронической почечной недостаточ-ностью. Уральский медицинский журнал 2011;2:124–127).

13. Endo A. A historical perspective on the discovery of statins. Proc Jpn Acad Ser B Phys Biol Sci 2010;86:484–493. DOI: 10.2183/pjab.86.484.

14. Trifirò G., Sultana J., Giorgianni F. et al. Chronic kidney disease requiring healthcare services: a new approach toevaluate epidemiology of renal disease. Biomed Res Int 2014;2014:268362. DOI: http://dx.doi.org/10.1155/2014/268362.

15. Sarnak M.J., Levey A.S., Schoolwerth A.C. et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108(17):2154– 2169. DOI:10.1161/01.CIR.0000095676.90936.80.

16. Go A.S., Chertow G.M., Fan D. et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351(13):1296–1305. DOI: 10.1056/NEJMoa041031.

17. Hillege H.L., Fidler V., Diercks G.F. et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002;106:1777–1782. DOI: https://doi.org/10.1161/01.CIR.0000031732.78052.81.

18. Menon V., Gul A., Sarnak M.J. Cardiovascular risk factors in chronic kidney disease. Kidney Int 2005;68(40):1413–1418. DOI: https://doi.org/10.1111/j.1523-1755.2005.00551.x.

19. Vaziri N.D. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 2006;290(2):F262–272. DOI:10.1152/ajprenal.00099.2005.

20. Zhdanova T.V., Borzunova N.S., Nazarov A.V. Characteristics of lipid metabolism in patients with chronic kidney disease and the effect of lipid-lowering drugs on renal hemodynamics. Atherosclerosis and dyslipidemia 2014;4:5–13. Russian (Жданова Т.В. Борзунова Н.С., Назаров А.В. Особенности липидного обме-на у пациентов с хронической болезнью почек и влияние гипо-липиде мических препаратов на почечную гемодинамику. Атеро-склероз и дислипидемии 2014;4:5–13).

21. Liu Y., Coresh J., Eustace J.A. et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004;291(4):451–459. DOI: 10.1001/jama.291.4.451.

22. Chu M., Wang A.Y., Chan I.H. et al. Serum small-dense LDL abnormalities in chronic renal disease patients. Br J Biomed Sci 2012;69(3):99–102.

23. Lamarche B., Lemieux I., Després J.P. The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, pathophysiology and therapeutic aspects. Diabetes Metab 1999;25:199–211. DOI: DM-08-1999-25-3-1262-3636-101019-ART69.

24. Pandya V., Rao A., Chaudhary K. Lipid abnormalities in kidney disease and management strategies. World J Nephrol 2015;4(1):83–91. DOI: 10.5527/wjn.v4.i1.83.

25. Mead J.R., Irvine S.A., Ramji D.P. Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med 2002;80(12):753–769. DOI: https://doi.org/10.1007/s00109-002-0384-9.

26. Nordestgaard B.G., Tybjaerg-Hansen A. IDL, VLDL, chylomicrons and atherosclerosis. Eur J Epidemiol 1992;8:92–98.

27. Milionis H.J., Elisaf M.S., Tselepis A. et al. Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with renal failure. Am J Kidney Dis 1999;33(6):1100–1106. DOI: https://doi.org/10.1016/S0272-6386(99)70147-2.

28. Rudel L.L., Shelness G.S. Cholesterol esters and atherosclerosis – a game of ACAT and mouse. Nat Med 2000;6(12):1313–1314.

29. Vaziri N.D., Liang K., Parks J.S. Down-regulation of hepatic lecithin:cholesterol acyltransferase gene expression in chronic renal failure. Kidney Int 2001;59(6):2192–2196. DOI: https://doi.org/10.1046/j.1523-1755.2001.00734.x.

30. Jonas A. Lecithin cholesterol acyltransferase. Biochim Biophys Acta 2000;1529(1):245–256. DOI: https://doi.org/10.1016/S1388-1981(00)00153-0.

31. Liang K., Oveisi F., Vaziri N.D. Role of secondary hyperparathyroidism in the genesis of hypertriglyceridemia and VLDL receptor deficiency in chronic renal failure. Kidney Int 1998;53(3):626–630. DOI: https://doi.org/10.1046/j.1523-1755.1998.00786.x.

32. Lacour B., Roullet J.B., Liagre A.M. et al. Serum lipoprotein disturbances in primary and secondary hyperparathyroidism and effects of parathyroidectomy. Am J Kidney Dis 1986;8(6):422–429. DOI: https://doi.org/10.1016/S0272-6386(86)80169-X.

33. Baigent C., Keech A., Kearney P.M. et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366(9493):1267–1278. DOI: 10.1016/S0140/6736(05)-67394-1.

34. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):23–33. DOI: https://doi.org/10.1016/S0140-6736(02)09328-5.

35. Sever P.S., Dahlöf B., Poulter N.R. et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the AngloScandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361(9364):1149–1158. DOI: https://doi.org/10.1016/S0140-6736(03)12948-0.

36. Tonelli M., Isles C., Curhan G.C. et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004;110:1557–1563. DOI: https://doi.org/10.1161/01.CIR.0000143892.84582.60.

37. Shepherd J., Kastelein J.J., Bittner V. et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 2008;51(15):1448–1454. DOI: https://doi.org/10.1016/j.jacc.2007.11.072.

38. Koren M.J., Davidson M.H., Wilson D.J. et al. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Am J Kidney Dis 2009;53(5):741–750. DOI: https://doi.org/10.1053/j.ajkd.2008.11.025.

39. Ridker P.M., MacFadyen J., Cressman M., Glynn R.J. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated highsensitivity C-reactive protein: a secondary analysis from the JUPITER ( Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol 2010;55(12):1266–1273. DOI: https://doi.org/10.1016/j.jacc.2010.01.020.

40. Holdaas H., Fellström B., Jardine A.G. et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003;361(9374):2024–2031. DOI: https://doi.org/10.1016/S0140-6736(03)13638-0.

41. Holdaas H., Fellström B., Cole E. et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant 2005;5(12):2929–2936.

42. Wanner C., Krane V., März W. et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353(3):238–248. DOI: 10.1056/NEJMoa043545.

43. Fellström B.C., Jardine A.G., Schmieder R.E. et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360(14):1395–1407. DOI: 10.1056/NEJMoa0810177.

44. Buemi M., Lacquaniti A., Bolignano D. et al. Dialysis and the elderly: an underestimated problem. Kidney Blood Press Res 2008;31(5):330–336. DOI: 10.1159/000164277.

45. Baigent C., Landray M.J., Reith C. et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial. Lancet 2011;377(9784):2181–2192. DOI: https://doi.org/10.1016/S0140-6736(11)60739-3.

46. Keane W.F., Mulcahy W.S., Kasiske B.L. et al. Hyperlipidemia and progressive renal disease. Kidney Int Suppl 1991;31:S41–S48.

47. Kasiske B.L., O’Donnell M.P., Cleary M.P., Keane W.F. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 1988;33(3):667–672. DOI: https://doi.org/10.1038/ki.1988.51.

48. Blom D., Averna M., Meagher E. et al. Long-term efficacy and safety of lomitapide for the treatment of homozygous familial hypercholesterolemia: results of the Phase 3 Extension Trial. Presented at: American Heart Association Scientific Sessions; Orlando, Floroda. Abstract 12450. 2015.

49. Yoshimura A., Inui K., Nemoto T. et al. Simvastatin suppresses glomeru lar cell proliferation and macrophage infiltration in rats with mesangial proliferative nephritis. J Am Soc Nephrol 1998;9(11):2027–2039.

50. Mänttäri M., Tiula E., Alikoski T., Manninen V. Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension 1995;26(4):670–675. DOI: https://doi.org/10.1161/01.HYP.26.4.670.

51. Muntner P., Coresh J., Smith J.C. et al. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 2000;58(1):293–301. DOI: https://doi.org/10.1046/j.1523-1755.2000.00165.x.

52. Schaeffner E.S., Kurth T., Curhan G.C. et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 2003;14(8):2084–2091.

53. Bianchi S., Bigazzi R., Caiazza A., Campese V.M. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003;41(3):565–570. DOI: https://doi.org/10.1053/ajkd.2003.50140.

54. Haynes R., Lewis D., Emberson J. et al. Effects of lowering LDL cholesterol on progression of kidney disease. J Am Soc Nephrol 2014;25(8):1825–1833. DOI: 10.1681/ASN.2013090965.

55. Rahman M., Yang W., Akkina S. et al. Relation of serum lipids and lipoproteins with progression of CKD: the CRIC study. Clin J Am Soc Nephrol 2014;9:1190–1198. DOI: 10.2215/CJN.09320913.

56. Sanguankeo A., Upala S., Cheungpasitporn W. et al. Effects of statins on renal outcome in chronic kidney disease patients: a systematic review and meta-analysis. PLoS ONE 2015;10:e0132970.

57. Su X., Zhang L., Lv J. et al. Effect of statins on kidney disease outcomes: a systematic review and meta-analysis. Am J Kidney Dis 2016;67:881–892. S0272-6386(16)00132-3 [pii].

58. Lacquaniti A., Bolignano D., Campo S. et al. Malnutrition in the elderly patient on dialysis. Ren Fail 2009;31:239–245. DOI: http://dx.doi.org/10.1080/08860220802669891.

59. Tirosh A., Golan R., Harman-Boehm I. et al. Renal function following three distinct weight loss dietary strategies during 2 years of a randomized controlled trial. Diabetes Care 2013;36(8):2225–2232. DOI: https://doi.org/10.2337/dc12–1846.

60. Yuzbashian E., Asghari G., Mirmiran P. et al. Associations of dietary macronutrients with glomerular filtration rate and kidney dysfunction: Tehran lipid and glucose study. J Nephrol 2015;28(2):173–180.

61. Bellinghieri G., Bernardi A., Piva M. et al. Metabolic syndrome after kidney transplantation. J Ren Nutr 2009;19(1):105–110. DOI: https://doi.org/10.1053/j.jrn.2008.10.002

62. Iseki K., Yamazato M., Tozawa M., Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 2002;61:1887–1893. https://doi.org/10.1046/j.1523-1755.2002.00324.x.

63. Ricciardi C.A., Lacquaniti A., Cernaro V. et al. Salt-water imbalance and fluid overload in hemodialysis patients: a pivotal role of corin. Clin Exp Med 2016;16:443–449. DOI: 10.1007/s10238-015-0374-1.

64. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285(19):2486–97. PMID:11368702.

65. Stone N.J., Robinson J.G., Lichtenstein A.H. et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129 (25 Suppl.2):S1–45.

66. Tonelli M., Wanner C., Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline. Ann Intern Med 2014;160(3):182.

67. Wanner C., Tonelli M., Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int 2014;85(6):1303–1309.

68. Phillips M.I., Costales J., Lee R.J. et al. Antisense Therapy for Cardiovascular Diseases. Curr Pharm Des 2015;21(30):4417–4426.

69. Thomas G.S., Cromwell W.C., Ali S. et al. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2013;62(23):2178–2184. DOI: https://doi.org/10.1016/j.jacc.2013.07.081.

70. Cuchel M., Meagher E.A., du Toit Theron H. et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013;381(9860):40–46. DOI: https://doi.org/10.1016/S0140-6736(12)61731-0.

71. Blom D., Averna M., Meagher E. et al. Long-term efficacy and safety of lomitapide for the treatment of homozygous familial hypercholesterolemia: results of the Phase 3 Extension Trial. Presented at: American Heart Association Scientific Sessions; Orlando, Floroda. Abstract 12450. 2015;132:A12450.

72. Robinson J.G., Farnier M., Krempf M. et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372(16):1489–1499. DOI: 10.1056/NEJMoa1501031.

73. Sabatine M.S., Giugliano R.P., Wiviott S.D. et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1500–1509. DOI: 10.1056/NEJMoa1500858.

74. Ballantyne C.M., Neutel J., Cropp A. et al. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am J Cardiol 2015;115(9):1212–1221. DOI: https://doi.org/10.1016/j.amjcard.2015.02.006.

75. Barter P.J., Caulfield M., Eriksson M. et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357(21):2109–2122. DOI: 10.1056/NEJMoa0706628.

76. Schwartz G.G., Olsson A.G., Abt M. et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367:2089–2099. DOI: 10.1056/NEJMoa1206797.

77. Nicholls S.J., Ruotolo G., Brewer H.B. et al. Evacetrapib alone or in combination with statins lowers lipoprotein(a)and total and small LDL particle concentrations in mildly hypercholesterolemic patients. J Clin Lipidol 2016;10(3):519–527, e4. DOI: https://doi.org/10.1016/j.jacl.2015.11.014.

78. Cannon C.P., Shah S., Dansky H.M. et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010;363(25):2406–2415.DOI: 10.1056/NEJMoa1009744.


Для цитирования:


Айтбаев К.А., Муркамилов И.Т., Фомин В.В. Гиполипидемическая терапия при хронической болезни почек: влияние на риск развития сердечно-сосудистых заболеваний и дисфункцию почек. Кардиология. 2019;59(2):79-87. https://doi.org/10.18087/cardio.2019.2.10231

For citation:


Aitbaev K.A., Murkamilov I.T., Fomin V.V. Hypolipidemic Therapy and Chronic Kidney Disease: Effects on Cardiovascular Risks and Renal Dysfunction. Kardiologiia. 2019;59(2):79-87. (In Russ.) https://doi.org/10.18087/cardio.2019.2.10231

Просмотров: 652


ISSN 0022-9040 (Print)
ISSN 2412-5660 (Online)